Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors

Archives of Gynecology and Obstetrics

Volumn 285, Issue 5, 2012, Pages 1397-1402

  Moegele, M ^a   Buchholz, S ^a   Seitz, S ^a   Ortmann, Olaf ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Aromatase inhibitor; Breast cancer; Hormone therapy; Vaginal estrogen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CONJUGATED ESTROGEN; DIENESTROL; ESTRADIOL; ESTRIOL; ESTROGEN; EXEMESTANE; GESTAGEN; LETROZOLE; PLACEBO; POLYCARBOPHIL; TIBOLONE; ESTROGEN RECEPTOR; HORMONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ARTICLE; BEDTIME DOSAGE; BREAST CANCER; BREAST SURGERY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; CYSTITIS; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DYSPAREUNIA; ENDOMETRIUM HYPERPLASIA; ESTRADIOL BLOOD LEVEL; FEMALE SEXUAL DYSFUNCTION; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; MENOPAUSAL SYNDROME; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VAGINA ATROPHY; VAGINAL DRYNESS; VAGINITIS; ABSENCE OF SIDE EFFECTS; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVOR; CONTACT DERMATITIS; DRUG EFFICACY; DRUG SAFETY; ESTROGEN THERAPY; GENITAL SYSTEM EXAMINATION; MENSTRUAL CYCLE; QUALITY OF LIFE; RISK FACTOR; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; VAGINA DISEASE; VAGINA PESSARY; VAGINA RING; VAGINAL IRRITATION; VAGINAL PRURITUS; VASOMOTOR DISORDER;

ADMINISTRATION, INTRAVAGINAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; VAGINAL DISEASES;

EID: 84862762984     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-011-2181-6     Document Type: Article

References (73)

1. International Agency for Research on Cancer (iarc). GLOBOCAN 2008: breast cancer incidence and mortality worldwide. http:// globocan.iarc.fr/factsheets/ cancers/breast.asp. Accessed 23 January 2011
2. Robert Koch Institut Krebs in Deutschland 2005/2006 Häu Wgkeit und Trends, 7. Ausgabe. http://www.edoc.rki.de/documents/ rki-fv/re2v Z21t28Ir8Y/.../22a JOd Ynm XV0I.pdf. Accessed 23 January 2011
3. Rossin-Amar B (2000) Vaginal dryness in the menopausal woman (physiological and psychological aspects). Gynecol Obstet Fertil 28:245-249 (Pubitemid 30216868)
4. Berman JR, Berman LA, Werbin TJ, Goldstein I (1999) Female sexual dysfunction: anatomy, physiology, evaluation and treatment options. Curr Opin Urol 9:563-568 (Pubitemid 30060207)
5. Joslyn SA (2002) Hormon receptors in breast cancer: Racial differences in distribution and survival. Breast Cancer Res Treat 73:45-59 (Pubitemid 34548165)
6. Forbes JF, Cuzick J, Buzdar A et al (2008) Arimidex, tamoxifen, alone or in combination (ATAC) trialists' group. effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53
7. Kendall A, Dowsett M, Folkerd E, Smith I (2006) Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 17:584-587
8. Fallow Weld L, Cella D, Cuzick J et al (2004) Quality of life of postmenopausal women in the arimidex, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 22:4261-4271 (Pubitemid 41185147)
9. Ganz PA, Rowland JH, Desmond K et al (1998) Life after breast cancer: understanding women's health- related quality of life and sexual functioning. J Clin Oncol 16:501-514 (Pubitemid 28135592)
10. HöZer D, Lusek R, Berthold HK, Tiaden JD (2003) Arzneimittelkommission der Deutschen Ärzteschaft 2003. Hormontherapie im Klimakterium. Therapieempfehlungen. Arzneiverordnung in der Praxis 3:19-26
11. New Zealand Guideline Group (NZGG) ( 2001) Best practice evidence- based guideline. The appropriate prescribing of hormone replacement therapy. Published May ISBN: 0-473-44714185
12. North American Menopause Society (NAMS Board) (2007) Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of the North American Menopause Society. Menopause 14:168-182
13. North American Menopause Society (NAMS Board) (2008) Estrogen and progestogen use in post- menopausal women: July 2008 position statement of the North American Menopause Society. Menopause 15:584-603
14. Collins JA, Blake JM, Crosignani PG (2005) Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 11:545-560 (Pubitemid 41631306)
15. Eberhardt S, Kulp W, von der Schulenburg JM, et al (2007) Hormone zur Therapie von Beschwerden im Klimakterium und zur Primärprävention von Erkrankungen in der Postmenopause. http:/ /gripsdb.dimdi.de/de/hta/hta-berichte/ hta127-bericht-de.pdf. Accessed 23 January 2011
16. Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA, The Cochrane HT Study Group (2005) Long-term hormone therapy for perimenopausal and postmenopausal women (review). Cochrane Database Syst Rev 3:CD004143
17. Farquhar CM, Marjoribanks J, Lethaby A, Lamberts Q, Suckling JA, and the Cochrane HT Study Group (2008) Long-term hormone therapy for perimenopausal and postmenopausal women (review). In: new search for studies completed, conclusions not changed. The Cochrane Library. 2:CD004143
18. Greiser CM, Greiser EM, Dören M (2005) Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials. Human Reprod Update 11:561-573 (Pubitemid 41631307)
19. IARC Monographs on the evaluation of carcinogenic risks to humans: combined estrogen- progestogen contraceptives and combined estrogen-progestogen menopausal therapy. (2007) 91 http:// www.monographs.iarc.fr/ENG/Meetings/ vol100-listagents.pdf
20. Lee SA, Ross RK, Pike MC (2005) An overview of menopausal oestrogen- progestin hormone therapy and breast cancer risk. Br J Cancer 92:2049-2058 (Pubitemid 40897429)
21. Shah NR, Borenstein J, Dubois RW (2005) Postmenopausal hormone therapy and breast cancer: a systematic review and metaanalysis. Menopause 12:668-678 (Pubitemid 41669118)
22. Beral V (2003) Million Women Study Collaborators: breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419-427 (Pubitemid 36999703)
23. Erratum in: Lancet 2003; 362:1160
24. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R, Chlebowski RT, Gass M, La Croix A, Manson JE, Prentice RL, Rossouw J, Stefanick ML (2008) Health risks and bene Wts 3 years after stopping randomized treatment with estrogen and progestin. JAMA 9:1036-1045 (Pubitemid 351347060)
25. Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670-1674 (Pubitemid 46631679)
26. Noss D, Ortmann O (2009) Hormone therapy (HT) and Cancer. J Gynaecol Endokrinol 19:6-10
27. Holmberg L, Anderson H (2004) HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomized comparison: trial stopped. Lancet 363:453-455 (Pubitemid 38210063)
28. Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B et al (2009) LIBERATE Study Group: safety and e Ycacy of tibolone in breast-cancer patients with vasomotor symptoms: a doubleblind, randomized, non inferiority trial. Lancet Oncol. 10:135-146
29. Von Schoultz E, Rutqvist LE (2005) Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 97:533-535 (Pubitemid 40590435)
30. Vassilopoulou-Sellin R, Theriault R, Klein MJ (1997) Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol 65:89-93 (Pubitemid 27171558)
31. Wile AG, Opfell RW, Margileth DA (1993) Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 165:372-375
32. Stoll BA (1989) Hormone replacement therapy in women treated for breast cancer. Eur J Cancer Clin Oncol 25:1909-1913 (Pubitemid 20084201)
33. Powles TJ, Hickish T, Casey S, O'Brien M (1993) Hormone replacement after breast cancer. Lancet 342:60-61
34. Eden JA, Bush T, Nand S, Wren BG (1995) A case-controlled study of combined continuous hormone replacement therapy amongst women with a personal history of breast cancer. Menopause 2:67-72
35. Ursic-Vrscaj M, Bebar S (1999) A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. Eur J Surg Oncol 25:146-151 (Pubitemid 29182455)
36. Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN et al (1999) Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 17:1482-1487 (Pubitemid 29220855)
37. De Saia PJ, Brewster WR, Ziogas A, Anton-Culver H (2000) Breast cancer survival and hormone replacement therapy: a cohort analysis. Am J Clin Oncol 23:541-545 (Pubitemid 32429096)
38. Marsden J, Whitehead M, A'Hern R, Baum M, Sacks N (2000) Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? Fertil Steril 37:292-299 (Pubitemid 30060362)
39. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS (2001) Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 93:754-762 (Pubitemid 32514798)
40. Beckmann MW, Mohrmann T, Kuschel B et al (1998) Hormonersatztherapie (HRT) nach Mammakarzinomerkrankung Ergebnisse einer Beobachtungsstudie. Geburtshilfe Frauenheilkd 58:193-196 (Pubitemid 28212995)
41. Col N, Hirota L et al (2001) Hormone replacement therapy after breast cancer: a systemic review and quantitative assessment of risk. J Clin Oncol 19:2357-2363 (Pubitemid 32372327)
42. Decker D, Pettinga J et al (2003) Estrogen replacement therapy in breast cancer survivors: a matched-controlled series. Menopause 4:277-285 (Pubitemid 36870499)
43. Cardozo L, Bachmann G, Mc Clish D, Fonda D, Bigerson L (1998) Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the hormones and urogenital therapy commmittee. Obstet Gyncol 92:722-727 (Pubitemid 28440818)
44. Suckling J, Lethaby A, Kennedy R (2003) Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 4:CD001500
45. North American Menopause Society (2007) Menopause practice: a clinican's guide, 3rd edn edn. North American Menopause Society, May Weld Heights
46. Nilsson K, Heimer G (1992) Low- dose oestradiol in the treatment of urogentital oestrogen de Wciency- a pharmacokinetic and pharmacodynamic study. Maturitas 15:121-127
47. Sindberg P, Rasmussen H (1992) Low- dose 17 - estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur J Obstetet Gynecol 44:137-144
48. Ascenzi P, Bodeci A, Marino M (2006) Structure- function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects 27:299-402 (Pubitemid 44255847)
49. Ruggiero RJ, Likis FE (2002) Estrogen: physiology, pharmacology, and formulations for replacement therapy. J Midwifery Women's Health 47:130-138
50. Van der Vies J (1982) The pharmacology of oestriol. Maturitas. 4:291-299 (Pubitemid 13189099)
51. Babuna C, Aksu MF, Erez R (1982) Management of lower genital tract atrophy with a vaginal cream containing oestriol. In: The menopause: clinical endocrinological and pathophysiological aspects. Academic Press, London, pp 557-562
52. Boselli F, Volpe A, Genazzani AR (1987) Topical therapy: estriol vaginal cream in postmenopausal women: gynecological endocrinology. Parthenon publishing, Carnforth, pp 687-694
53. Boselli F, Cicoli C, Volpe A, Genazzani AR (1987) Endometrial morphology after long-term topical oestriol therapy in postmenopausal women. In: Abstracts of the 5th International Congress on the Menopause Sorrento. Parthenon Publishing, Carnforth. p 75
54. Genazzani AR, Inaudi P, La Rosa R, De Leo V, Ricci-Danero MG, Danero S (1980) Estriol and menopause-clinical and endocrinological results of vaginal administration. In: International symposium on the menopause: clinical, endocrinological and pathophysiological aspects
55. Gerbaldo D, Ferraiolo A, Croce S, Truini M, Capitanio GL (1991) Endometrial morphology after 12 months of vaginal oestriol therapy in postmenopausal women. Maturitas 13:269-274
56. Kicovic PM, Cortes-Prieto J, Milojevic S, Haspels AA, Aljinovic A (1980) The treatment of postmenopausal vaginal atrophy with Ovestin® vaginal cream or suppositories: clinical, endocrinological and safety aspects. Maturitas 2:275-282 (Pubitemid 11170804)
57. Lauritzen C (1979) Erfahrungen mit einer oestriol-vaginalcreme. Ther Gegenw 118:567-577
58. Luisi M, Franchi F, Kicovic PM (1980) A group-comparative study of effects of Ovestin® cream versus premarin cream in postmenopausal women with vaginal atrophy. Maturitas 2:311-319 (Pubitemid 11170808)
59. Mattsson LA, Cullberg G (1983) A clinical evaluation of treatment with estriol vaginal cream versus suppository in postmenopausal women. Acta Obstet Gynecol Scand 62:397-401 (Pubitemid 14213524)
60. Foidart JM, Vervliet J, Buytaert Ph (1991) EYcacy of sustainedrelease vaginal oestriol in alleviating urogenital and systemic climacteric complaints. Maturitas 13:99-107
61. Fink RS, Collins WP, Papadaki L, O'Reilly B, Ginsburg J (1985) Vaginal estriol: effective menopausal therapy not associated with endometrial hyperplasia. J Gynaecol Endocrinol 1:1-2
62. Pfeiler G, Glatz C, Königsberg R et al (2011) Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. Climacteric 14:339-344
63. Vooijs GP, Geurts TBP (1995) Review of the endometrial safety during intravaginal treatment with estriol. Eur J Obstet Gynecol Reprod Biol 62:101-106
64. Kendall A, Dowsett M, Folkerd E, Smith I (2006) Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 17:584-587
65. Labrie F, Cusan L, Gomez JL et al (2009) Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause 16:30-36
66. Derzko C, Elliott S, Lam W (2007) Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol 14:20-40
67. Bachmann GA, Nevadunsky NS (2000) Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 61:3090-3096 (Pubitemid 30347020)
68. Murray A, Freedman MA (2008) Vaginal p H, estrogen and genital atrophy. Menopause Manag 17:9-11
69. American College of Obstetricians and Gynaecologists, Committee on Patient Education (2007) Disorders of the vulva. ACOG, Washington, DC http://www.acog.org/publications/patient- education/ bp088.cfm. Accessed 23 January 2011
70. Bygdeman M, Swahn ML (1996) Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 23:259-263 (Pubitemid 26000605)
71. Society of Obstetricians, Gynaecologists of Canada (2005) Clinical practice guidelines: the detection and management of vaginal atrophy. Int J Gynaecol Obstet 88:222-228
72. Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Julia MD (2005) Management of post- menopausal vaginal atrophy and atrophic vaginitis. Maturitas 52:46-52
73. Suckling J, Lethaby A, Kennedy R (2003) Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 4:CD001500